All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Envelope glycoprotein GP120 (or gp120) is a glycoprotein exposed on the surface of the HIV envelope. GP120 is essential for virus entry into cells as it plays a vital role in attachment to specific cell surface receptors. This molecule has specific interaction with the CD4 receptor of helper T cells. Binding to CD4 induces the start of a cascade of conformational changes in gp120 and gp41 that lead to the fusion of the viral with the host cell membrane. Since CD4 receptor binding is the most obvious step in HIV infection, gp120 was among the first targets of HIV vaccine research.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-ZP1850 | Anti-HIV-1 gp120 (GP44) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | GP44 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1851 | Anti-HIV-1 gp120 (GP44) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | GP44 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1852 | Anti-HIV-1 gp120 (PGT145) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | PGT145 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1853 | Anti-HIV-1 gp120 (PGT145) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | PGT145 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1854 | Anti-HIV-1 gp120 (F56/P6G4) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | F56/P6G4 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1855 | Anti-HIV-1 gp120 (F56/P6G4) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | F56/P6G4 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1856 | Anti-HIV-1 gp120 (25C2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 25C2 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1878 | Anti-HIV-1 gp120 (R56) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | R56 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1879 | Anti-HIV-1 gp120 (R56) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | R56 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1880 | Anti-HIV-1 gp120 (1.4E) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 1.4E | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1881 | Anti-HIV-1 gp120 (1.4E) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 1.4E | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1882 | Anti-HIV-1 gp120 (CAP257-RH1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CAP257-RH1 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1883 | Anti-HIV-1 gp120 (CAP257-RH1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CAP257-RH1 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1884 | Anti-HIV-1 gp120 (PGT121) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | PGT121 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1885 | Anti-HIV-1 gp120 (PGT121) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | PGT121 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1886 | Anti-HIV-1 gp120 (3BNC62) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 3BNC62 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1887 | Anti-HIV-1 gp120 (3BNC62) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 3BNC62 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1888 | Anti-HIV-1 gp120 (3BNC55) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 3BNC55 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1889 | Anti-HIV-1 gp120 (3BNC55) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 3BNC55 | Human | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP1890 | Anti-HIV-1 gp120 (59.1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 59.1 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION